Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-Gastric/Gastroesophageal Junction Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01364493
What this trial is testing

Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer

Who this might be right for
Gastric Cancer
Peking University 51
Early research (Phase 1)WithdrawnNCT02205463
What this trial is testing

KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer

Who this might be right for
Esophageal CancerStomach Cancer
NYU Langone Health
Large-scale testing (Phase 3)Looking for participantsNCT07431281
What this trial is testing

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaEsophageal Cancer
AstraZeneca 2,130
Large-scale testing (Phase 3)Ended earlyNCT01641939
What this trial is testing

Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 415
Early research (Phase 1)UnknownNCT04460456
What this trial is testing

SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Who this might be right for
HER2 Positive Solid Tumors
Silverback Therapeutics 58
Testing effectiveness (Phase 2)WithdrawnNCT02274012
What this trial is testing

Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment

Who this might be right for
HER-2 Positive Gastric CancerGastrooesophageal CancerEsophageal Cancer
Columbia University
Testing effectiveness (Phase 2)Active Not RecruitingNCT05476796
What this trial is testing

Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

Who this might be right for
Gastric AdenocarcinomaEsophagus AdenocarcinomaGastroesophageal Junction Adenocarcinoma
UNICANCER 118
Large-scale testing (Phase 3)Study completedNCT04082364
What this trial is testing

Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

Who this might be right for
Gastric CancerGastroesophageal Junction CancerHER2-positive Gastric Cancer
MacroGenics 82
Large-scale testing (Phase 3)Looking for participantsNCT07673887
What this trial is testing

ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc. 570
Early research (Phase 1)Looking for participantsNCT04389632
What this trial is testing

Sigvotatug Vedotin in Advanced Solid Tumors

Who this might be right for
Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer 1,006
Early research (Phase 1)Looking for participantsNCT05872295
What this trial is testing

IKS014 in Advanced Solid Tumors That Express HER2

Who this might be right for
Breast CancerGastric CancerGastroesophageal-junction Cancer
Iksuda Therapeutics Ltd. 165
Testing effectiveness (Phase 2)UnknownNCT05113459
What this trial is testing

Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer（RC48-C018）

Who this might be right for
Gastric Cancer
Guoxin Li 40
Testing effectiveness (Phase 2)Ended earlyNCT01579578
What this trial is testing

Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer

Who this might be right for
Metastatic, Gastric or Gastro-oesophageal Junction, Cancer
AstraZeneca 39
Not applicableLooking for participantsNCT06158919
What this trial is testing

PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer

Who this might be right for
Gastric Cancer/Adenocarcinoma of Esophagogastric Junction
Fudan University 58
Testing effectiveness (Phase 2)Study completedNCT02795988
What this trial is testing

IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer

Who this might be right for
Gastrointestinal NeoplasmsAdenocarcinoma
Imugene Limited 64
Early research (Phase 1)Study completedNCT03821233
What this trial is testing

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Who this might be right for
HER2-expressing Cancers
Zymeworks BC Inc. 112
Post-approval studies (Phase 4)Not Yet RecruitingNCT07768358
What this trial is testing

Tucatinib Continuation Study

Who this might be right for
HER2-positive Breast CancerCervical CancerBiliary Tract Neoplasms+4 more
Pfizer 175
Testing effectiveness (Phase 2)Ended earlyNCT04467515
What this trial is testing

Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer

Who this might be right for
Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
Precirix 13
Testing effectiveness (Phase 2)Ended earlyNCT01774851
What this trial is testing

MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Who this might be right for
HER-2 Gene AmplificationEsophagus CancerGastroesophageal Junction Cancer+1 more
Merrimack Pharmaceuticals 84
Testing effectiveness (Phase 2)Ended earlyNCT05207722
What this trial is testing

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Who this might be right for
Metastatic HER2 Positive Gastroesophageal Junction Cancer
Celularity Incorporated 1
Next Page